ADx NeuroSciences and Alamar Biosciences Collaborate to Accelerate Clinical Breakthroughs with Tailored Biomarker Assay Solutions
October 28, 2024,Gent, Belgium & Fremont, Calif., United States : ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a leader in ultra-sensitive immunoassay technologies, today announced a partnership in the development of customized biomarker assay solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) …